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TECHNICAL NOTE
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Anticoagulation by heparin administration is the primary
method employed to prevent clotting in the extracorporeal
circuit during hemodialysis [1, 2]. The heparin infusion regimen
usually consists of a bolus loading dose followed by either
additional boluses or continuous infusion into the arterial line of
the dialyzer. The level of anticoagulation may be monitored by
measuring the activated clotting time (ACT) for a sample of
whole blood drawn from the extracorporeal circuit. In patients
not at risk of systemic anticoagulation, heparin is usually
administered to achieve and maintain an elevated ACT that is
typically 150% of the baseline level. A series of ACT measure-
ments obtained during the first few hemodialysis treatments a
patient receives may be used in a mathematical modeling
approach to determine the average heparin requirement for the
individual patient [2]. Mathematical modeling of heparin re-
quirements is particularly important when patients are at in-
creased risk of complications from systemic heparinization. In
these instances, anticoagulation is more closely monitored, and
the heparin dose is decreased to keep the ACT at 125% of the
baseline [3].
However, applying the mathematical modeling approach to
determine the heparin requirements requires laborious calcula-
tions, or the use of nomograms, and manual recording of the
heparin dosage and its timing [4]. Since the patient's heparin
requirements may change over time, they should be reassessed
monthly and at any time untoward clotting or hemorrhage
episodes occur. For hemodialysis in acute situations, there are
no past heparin dosage requirements available for guidance; it is
difficult to apply the mathematical modeling approach during
acute hemodialysis to maintain precise control of anticoagula-
tion.
This paper describes the use of a computer-controlled system
that uses sparse ACT measurements as the basis for automati-
cally adjusting the heparin infusion rate to provide a target level
of anticoagulation. The patient receives an infusion regimen
that would achieve and maintain a desired ACT in a mathemat-
ical model of the patient response to heparin infusion. The
infusion regimen is delivered by means of a computer-con-
trolled syringe pump. A menu-driven program allows the oper-
ator to enter patient data, verify parameters such as the syringe
size and concentration of heparin in the syringe, and direct the
operation of the adaptive control system. Before heparin ad-
ministration, the patient's baseline ACT is measured, and a
setpoint is determined and entered into the system. The height,
weight, and sex of the patient are entered into the computer
system for use in determining the initial model parameter
estimates. After data entry, the operator selects a menu entry to
begin drug infusion. The system then delivers the infusion
regimen computed to achieve the target response in the patient
model. When an ACT measurement is to be used for adaptive
control, the operator selects the appropriate menu entry and
enters the ACT measurement and the time at which the corre-
sponding blood sample was drawn into the system. The system
then automatically estimates the parameters for the individual
patient, adapts the model parameters to the new estimates, and
adjusts the infusion rate as required to move the ACT to the
target level. If the measured ACT is below the target, heparin is
infused rapidly to raise the model-based ACT prediction to the
target level, and then a continuous infusion is begun at a rate
that would maintain the target response for the model. If the
measured ACT is above the target, the infusion rate is set to
zero until the predicted ACT falls to the target, and then a
continuous infusion is begun at a rate that would maintain the
target response for the model. The model parameters are
estimated using a Bayesian method in which a new parameter
estimate is calculated by weighing the confidence in the ACT
measurement against the confidence in the current estimate of
the model parameters [5, 6]. Bayesian estimation is especially
useful in situations where model parameters are estimated
based on sparse measurements of patient response [7].
Methods
A mathematical model of the ACT response to heparin
infusion was used to determine the heparin infusion regimen.
Individualization of heparin therapy was accomplished by esti-
mating model parameters and subsequently adjusting the infu-
sion regimen based on sparse ACT measurements.
Modeling
In hemodialysis patients, heparin pharmacokinetics may be
described using a one compartment model [2—4]. The time rate
of change of the compartmental concentration is
dC
—
= —k10C + — (Eq. 1)
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where i is the heparin infusion rate, k10 is the elimination rate
constant, and Vd is the apparent volume of distribution, which
corresponds to the blood volume [8]. Pharmacokinetic studies
have shown that the heparin half-life increases with dose if the
dose is increased over a large range. This nonlinear elimination
is primarily due to the value of k10 decreasing with increases in
the heparin dose and the resulting heparin concentration [9].
Linear models have been adequate for clinical application in
hemodialysis where the heparin doses are relatively low such
that nonlinear elimination is probably not significant [2—4].
The response to heparin infusion, R (sec), is the magnitude of
the ACT elevation above the baseline value
R = ACT — ACTBASELINE
The sensitivity parameter, S, may be calculated from the
response to a bolus dose of heparin, D, using
R
S=15
Since R is related to the heparin concentration by
R = SCVd
the time rate of change of R is
dR
—k10R+Si
The S parameter may be written in terms of Vd as
SLOPE
Vd
where SLOPE is the ACT elevation produced by a specific
heparin dose in a known volume of blood. We have determined
the mean value for SLOPE in the patient population in which
the adaptive control system would be tested. After measuring
the baseline ACT, administering a bolus dose of heparin, D, and
measuring the ACT five minutes later, the value of SLOPE for




where V was the blood volume predicted based on the pa-
tient's sex, weight, and height [10]. The mean value of SLOPE
in the patient population was 250 sec/U/mI. In this study, the
initial estimate of S was computed for each patient using the
blood volume predicted based on patient characteristics and the
mean value of SLOPE. The initial estimate for k10 was the mean
value of 0.9 hour1 that is frequently cited in the literature for
normal patients [4, 8]. The values for the parameters S and k10
are assumed to vary among patients according to a log-normal
distribution [3].
Simulation
The performance of the adaptive control system was initially
assessed in Monte Carlo simulations [11]. Model parameters for
a simulated patient population were assigned at random accord-
ing to a log-normal distribution. A sampling schedule that would
result in good control based on feedback of three ACT values
measured at 5, 30, and 90 minutes after the start of infusion was
determined in simulations by trial and error. Simulation results
demonstrated that adaptive control based on sparse measure-
ments might be used to achieve and maintain a target ACT with
a high degree of confidence.
Clinical trials
Adaptive control of anticoagulation was evaluated in twelve
male patients receiving chronic in-center hemodialysis. The
protocol was approved by the Institutional Review Board at
The University of Alabama at Birmingham and by the Birming-
ham Veteran's Affairs Medical Center. Informed consent was(Eq. 2) obtained for each patient.
All patients were dialyzed using the same equipment (model
A2008D, Fresenius, Concord, California, USA), dialysis tubing
(arterial venous blood tubing set, MediSystems Corp., San
Francisco, California, USA), and hollow-fiber dialyzer (C 101,
(Eq. 3) Terumo Medical Corp., Elkton, Maryland, USA). The extra-
corporeal circuit was primed using non-heparinized saline.
Before heparin administration the height and weight of the
patient were entered into the computer system for calculating
(Eq. 4) the 'd used in determining the initial estimate of the patient's S
parameter. Heparin (porcine heparin, 1000 U/mi, lot number
310100, Lyphomed, Inc., Rosemont, Illinois, USA) was deliv-
ered using adaptive control for the first 180 minutes of a routine
(Eq. 5) 240-minute hemodialysis procedure. Heparin infusion was ter-
minated at 180 minutes in all patients. For each patient, the
baseline ACT was determined (Hemochron® instrument, P215
plastic test tube with glass particle activator, International
Technidyne Corporation, Edison, New Jersey, USA) and a(Eq. 6) setpoint of 150% of the patient's baseline ACT was entered into
the computer system. Measurements of the ACT were obtained
from blood samples scheduled to be drawn at 5, 30, 60, 90, 120,
150, 180, 210, and 240 minutes after the start of heparin
infusion. Blood samples were drawn from the arterial line
(dialyzer inlet) to ensure that the anticoagulation status of the
patient was measured rather than that of blood from the dialysis
apparatus. At each sampling time, the average of the ACT
values for two blood samples was used as the ACT measure-
ment. Only those ACT measurements for the samples drawn at
(Eq 7) 5, 30, and 90 minutes were entered into the computer system
and used as the basis for parameter estimation and subsequent
infusion rate adjustment in adaptive control. Typically, ACT
measUrements and the corresponding sampling times were
entered into the computer system for adaptive control about
five minutes after a blood sample was drawn. For Bayesian
parameter estimation, the coefficient of variation of the mea-
surement error was assumed to be 5% and the coefficients of
variation for the S and k10 model parameters were assumed to
be 50%.
In the data analysis, all values were represented as mean
one standard deviation.
Results
In these studies, no patient suffered an untoward event. No
clotting was observed in the extracorporeal circuit. The predi-
alysis hematocrit was 31 4 percent. The baseline ACT was
152 10 seconds. Figure 1 shows the means and one standard
deviation bounds of the ACT measurements in blood samples
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obtained during adaptive control in twelve patients. During
adaptive control, measured ACT values were 150 11% of the
baseline ACT and the range was 127 to 176% of the baseline
ACT. The coefficient of variation of the measurement errors
was calculated to be 6.3% using 310 pairs of ACT measure-
ments. Therefore, for a measurement calculated from two
averaged values the coefficient of variation was 4.4%; a value of
5% was assumed in the design of the parameter estimator. The
variability in the measured data (Fig. 1) was due in part to
the measurement error (coefficient of variation of 4.4%). After
the final adjustment based on the 90 minute ACT measurement,
the heparin infusion rate was 2160 671 U/hr.
Discussion
This paper describes adaptive control of anticoagulation
based on three ACT measurements obtained during the hemo-
dialysis treatment. The adaptive control system precisely de-
livered the infusion regimen that would achieve the target ACT
in a time-optimal manner in a mathematical model of the ACT
response to heparin infusion. Subsequent adaptation based on
the model parameters estimated for the individual patient
ensured that the ACT was maintained at the target value with a
high degree of confidence.
The adaptive control system requires less time and effort to
use than is needed for clinical personnel to plan, monitor, and
implement a patient's therapy using the mathematical modeling
approach. Accurate delivery and recording of the infusion
regimen by a computer-controlled syringe pump eliminates
setting infusion rates by manual syringe pump adjustment and
eliminates manual recording of the infusion regimen. The Bay-
esian parameter estimation procedure correctly accounts for
the error in the ACT measurement; with the mathematical
modeling approaches in current use, the parameters are calcu-
lated assuming the ACT measurement error is zero.
No prior heparin requirements are available for guiding
heparinization during acute hemodialysis or during the first few
hemodialysis treatments that a patient receives. With the hep-
arinization protocols that are usually employed in patients at
risk from anticoagulation, it is difficult to maintain precise
control of the degree of anticoagulation because the desired
ACT elevation is so small that the information provided by the
ACT measurements may be limited by their accuracy. The
precise control of the degree of anticoagulation offered by the
computerized adaptive control system may be advantageous in
these situations.
The value of the sensitivity parameter calculated with equa-
tion 6 using the predicted blood volume based on patient
characteristics may be a more accurate prior estimate for an
individual patient than the mean value in the patient population.
Accurate prior knowledge of the sensitivity would result in
more precise control of ACT values early in the infusion than
would be achieved when an inaccurate estimate of this param-
eter is initially available.
The adaptive control system was designed assuming that the
pharmacokinetic system was not subject to time variations in
structure or parameter values. However, because the blood
volume decreases as fluid is removed from the patient during
hemodialysis, some variation in the model parameters over time
is anticipated, and may account for the slight increase in the
ACT over time (Fig. 1). However, this effect is not significant.
A linear model of the ACT response to heparin infusion was
utilized in the present study for adaptive control with a setpoint
of 150% of the baseline ACT. Nonlinear heparin elimination
may be encountered for setpoints that require much higher
doses of heparin. In these cases, an adjusted initial elimination
rate constant may be more accurate than the value used in the
present study.
Topics for future research include the extension and further
development of algorithms to provide improved control system
performance and utility. The estimate of a patient's elimination
rate constant could be used to calculate the time at which the
heparin infusion should be terminated in order to allow the ACT
to fall to a desired value at a specified time near the end of
dialysis [2, 4]. The times at which the samples are obtained
significantly affect the performance of the system in achieving
and maintaining a target ACT response [12]. The sampling
schedule calling for samples to be obtained at 5, 30, and 90
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Fig. 1. Means (circles), one standard
deviation bounds (bars), maximum (upper
dotted line) and minimum (lower dotted
line) of ACT measurements (N = 120) in
clinical trials of adaptive control of
anticoagulation during hemodialysis in
250 twelvepatients. The target ACT (dashed
line) was 150% of a patient's baseline
ACT.
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and 90 minute samples used for adaptation to perhaps 60 and
120 minutes, respectively, might provide feedback at times that
would result in more precise control of the ACT late in the
hemodialysis procedure than was observed in the clinical study
(Fig. 1). We are currently investigating methods for developing
improved sampling strategies that would ensure a specified
control system performance in maintaining the desired level of
anticoagulation and would optimize the sampling schedule for
an individual patient based on the measurements obtained
during the control period. Use of the adaptive control system in
the first few treatments that a patient receives to automatically
determine routine heparin requirements would obviate the need
for the manual recording and calculation required in the stan-
dard mathematical modeling approach. For determining heparin
requirements, the theory of optimal experiment design could be
applied to devise a sampling schedule that would specify the
times at which ACT measurements should be obtained in order
to achieve a desired degree of accuracy in the parameter
estimates [12]. There may be a high degree of uncertainty in the
model parameter estimates when only sparse measurements of
patient response are available [6]. Knowledge of the resulting
level of uncertainty in the predicted ACT response would allow
the physician to make better decisions regarding therapy and to
make better interpretation of concurrent indicators of the
patient's clinical status. We are currently developing forecast-
ing algorithms for computing a confidence interval that would
reflect the level of uncertainty in the model-based ACT predic-
tion. This work might also be extended to provide the basis for
computer-controlled heparin delivery in other applications
where precise control of the level of anticoagulation is desir-
able.
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